MX2016013680A - Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. - Google Patents

Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.

Info

Publication number
MX2016013680A
MX2016013680A MX2016013680A MX2016013680A MX2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A MX 2016013680 A MX2016013680 A MX 2016013680A
Authority
MX
Mexico
Prior art keywords
methods
lipid storage
storage disorders
compositions
treatment
Prior art date
Application number
MX2016013680A
Other languages
English (en)
Inventor
A Ioannou Yiannis
Altstiel Lawrence
R Crockford David
Kongsamut Sathapana
Original Assignee
Neurotrope Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotrope Bioscience Inc filed Critical Neurotrope Bioscience Inc
Publication of MX2016013680A publication Critical patent/MX2016013680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Abstract

Tratamiento de sujetos que tienen un trastorno por el almacenamiento de lípidos con una composición que comprende un activador de PKC, tal como briostatinas, briólogos y ácidos grasos pollinsaturados; por consiguiente, la presente descripción provee métodos para tratar a sujetos humanos que sufren de trastornos por el almacenamiento de lípidos, tal como la enfermedad de Niemann-Pick, administrando activadores de PKC; la presente descripción provee, de conformidad con ciertas modalidades, métodos que comprenden administrar a un sujeto con enfermedad de Niemann-Pick Tipo C, una cantidad farmacéuticamente efectiva de briostatina 1.
MX2016013680A 2014-04-18 2015-04-14 Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. MX2016013680A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US201461987360P 2014-05-01 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (1)

Publication Number Publication Date
MX2016013680A true MX2016013680A (es) 2017-07-05

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013680A MX2016013680A (es) 2014-04-18 2015-04-14 Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.

Country Status (9)

Country Link
US (3) US9724328B2 (es)
EP (1) EP3131543A4 (es)
JP (1) JP2017511387A (es)
KR (1) KR20170031653A (es)
CN (1) CN107072982A (es)
CA (1) CA2946115A1 (es)
IL (1) IL248494A0 (es)
MX (1) MX2016013680A (es)
WO (1) WO2015160851A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109982695A (zh) 2016-08-18 2019-07-05 国立大学法人奈良先端科学技术大学院大学 免疫调节剂
CA3097744A1 (en) * 2018-04-20 2019-10-24 Retrotope, Inc. Stabilized polyunsaturated compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040214A1 (en) 1999-11-30 2001-06-07 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
CN1678304B (zh) 2002-07-02 2012-06-27 布朗歇特洛克菲勒神经科学研究所 苔藓抑制素类化合物在制备用于活化PKC而增强sAPPα分泌和改善认知的药物中的应用
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
EP3403650A3 (en) 2008-07-28 2019-02-13 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20120156180A1 (en) 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
EP3967299A1 (en) * 2011-11-13 2022-03-16 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
US9833435B2 (en) 2014-03-27 2017-12-05 Blanchette Rockefeller Neurosciences Institute Compositions and methods to treat Niemann-Pick disease

Also Published As

Publication number Publication date
US20190201377A1 (en) 2019-07-04
IL248494A0 (en) 2016-12-29
CN107072982A (zh) 2017-08-18
WO2015160851A1 (en) 2015-10-22
US9724328B2 (en) 2017-08-08
CA2946115A1 (en) 2015-10-22
US20170172978A1 (en) 2017-06-22
EP3131543A1 (en) 2017-02-22
US20150297559A1 (en) 2015-10-22
JP2017511387A (ja) 2017-04-20
EP3131543A4 (en) 2017-12-20
KR20170031653A (ko) 2017-03-21

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
BR112015022197A2 (pt) tratamento de cataplexia
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
EA201692292A1 (ru) Соединения и композиции для стимулирования хондрогенеза
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
WO2015023691A3 (en) 4-methylumbelliferone treatment for immune modulation
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
PH12016501159A1 (en) Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
BR112013026644A2 (pt) método para a modulação da atividade de citocina
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.